Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Longyi Zhengqi Fang (also known as Longyi-Zhengqi Formula) is a Traditional Chinese Medicine (TCM) herbal compound developed by Longhua Hospital, affiliated with the Shanghai University of Traditional Chinese Medicine. Formulated based on the principle of strengthening the body's resistance to eliminate pathogenic factors, it is intended for the prevention and treatment of respiratory infectious diseases, specifically COVID-19 (new coronavirus pneumonia). Network pharmacology studies suggest the formula targets multiple pathways, notably regulating the inflammatory cytokine Interleukin-6 (IL-6) to mitigate the cytokine storm associated with severe viral infections. As a botanical mixture, it contains multiple active herbal components.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Longyi Zhengqi Fang.